Abstract: The subject matter of the invention is a human intestinal microbiota bacterium selected from bacteria in the Christensenellaceae family, bacteria of the genus Negativibacillus and bacteria of the genus Massiliomicrobiota, or a composition containing same, for use in the prevention and/or treatment of diseases characterized by excess 2-hydroxyglutarate in humans or animals.

Abstract: The invention relates to a bacterium of the Christensenellaceae family or of a composition containing same for use in the prevention and/or treatment of hypertriglyceridemia in humans or animals.

Abstract: The invention relates to a bacterium of the Christensenellaceae family, in particular of the genus Christensenella, or a composition containing same for use in the prevention and/or treatment of chronic inflammatory diseases and/or cancers in humans or animals.

Abstract: The invention relates to bacteria of the Christensenellaceae family and compositions containing same for their use in the prevention and/or treatment of renal insufficiency in humans or animals.

Abstract: The invention relates to bacteria of the Christensenellaceae family and to compositions including same for use in the prevention and/or treatment of pathological muscle loss and/or of at least one disease characterized by muscle loss in humans or animals.

Abstract: The present invention relates to uses of antagonists of Rspondin-3 (Rspo3) polypeptides or Rspondin-3 nucleic acids. The invention is based on the demonstration that partial deficiency of Rspo3 leads to a significant increase of bone mass. These results indicate a major role for Rspo3 as a bone anabolic marker or target. Thus, the invention also relates to the use of Rspo3 antagonists in the treatment of osteopenia disorders, particularly in conditions associated with increased bone resorption.

Abstract: The present invention relates to methods of diagnosis, therapy, and screening of new therapeutic compounds in the field of osteogenesis, based on the differential expression observed for the genes of the invention, represented by SEQ ID No 2, 7, 22, 25, 33, 35, 37, 38, 42, 47, 64, 69 or 77, 82, 97, 100, 108, 110, 112, 113, 117, 122, 139, 151, 158, 160, 172, 182, 184, 187, 188, 194.

Abstract: The present invention relates to methods for preventing and/or treating bone-related diseases in mammals, especially humans, using GSK-3? inhibitors. The invention also concerns methods for selecting in vitro and/or in vivo compounds useful for preventing and/or treating bone-related diseases in mammals, including humans.

Abstract: The present invention relates to methods of diagnosis, therapy, and screening of new therapeutic compounds in the field of osteogenesis, based on the differential expression observed for the genes of the invention, represented by SEQ ID No 1 to SEQ ID No 150, or SEQ ID No 151, 152 or 153, or SEQ ID No 154 to SEQ ID No 196, or SEQ ID No 197 to SEQ ID No 210, or SEQ ID No 211 to SEQ ID No 229, or SEQ ID No 230 to SEQ ID No 234, or SEQ ID No 235 to SEQ ID No 245.

Abstract: A bone strength and mineralization regulatory (“BSMR”) protein is provided that can exist in multiple forms and that affects bone density. Polymorphic gene sequences of the protein are provided that are diagnostic of predipostion to osteoporosis. Other detection tools, compositions and methods of their use also are provided for predicting, evaluating and altering bone strength and mineralization status. The invention provides new natural and synthetic pharmaceuticals that effect the BSMR regulatory pathway and improve bone status. Tools also are provided for finding new pharmaceuticals that operate by binding to BSMR and that activate and/or deactivate this protein's biological function related to osteoporosis and blood vessel formation.